P.S.K Biosciences Announces Positive Clinical Data for RP-ILD from its Exosome-Based Therapeutic Program

After more than ten months of concerted efforts from all parties involved, we have completed the enrollment, administration, and three-month follow-up for 10 patients with RP-ILD. RP-ILD is a clinically highly fatal pulmonary disease, often referred to as “the tumor among lung diseases.” Typically, the risk of death within the first few weeks after diagnosis is extremely high, with a reported mortality rate of 50–90% within 3–6 months according to clinical observations. Remarkably, all 10 enrolled patients who received treatment were discharged approximately two weeks after administration and remained stable during the subsequent three-month follow-up, with no need for rehospitalization. The clinical mortality rate in this treated cohort was 0%. Our precisely defined exosome subpopulation demonstrated highly encouraging clinical outcomes. Furthermore, no adverse clinical reactions were observed in any of the 10 patients.

P.S.K Biosciences
Corporate Communications
July 16, 2025